NCT03354754View on ClinicalTrials.gov

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

September 24, 2018

Study Completion Date

September 24, 2018

Conditions
Intra-abdominal Infections
Interventions
DRUG

LYS228

LYS228 IV infusion every 6 hours

DRUG

Standard of care therapy

IV infusion of standard of care antibiotics

Trial Locations (1)

08230

Novartis Investigative Site, Somers Point

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT03354754 - LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI) | Biotech Hunter | Biotech Hunter